Kimberly-Clark: The Cradle and the Courtroom

ISSUE 51 · JUNE 2, 2026 · KMB $99.14

In July 2025, Kimberly-Clark stock touched $144.23. On June 2, 2026, it trades at $99.14. That is a 31% drawdown in eleven months. The 52-week low is $92.42, hit in April. Market cap sits around $33 billion on approximately 335 million shares outstanding.

The decline has two named causes and one that the market hasn't fully priced.

Named cause 1: a $48.7 billion acquisition that the market didn't want. On November 2, 2025, Kimberly-Clark announced it would acquire Kenvue — the Johnson & Johnson consumer health spinoff that owns Tylenol, Listerine, Neutrogena, Aveeno, Band-Aid, and Benadryl — in a cash-and-stock deal valued at $48.7 billion in enterprise value. Each Kenvue share converts into 0.14625 shares of KMB stock plus $3.50 in cash, meaning Kimberly-Clark will issue roughly 280 million new shares and pay approximately $6.7 billion in cash. Existing KMB shareholders will own about 54% of the combined company. The stock fell 12.6% on the announcement day alone.

On January 29, 2026, shareholders of both companies voted overwhelmingly to approve — 96% of KMB shares present, 99% of Kenvue shares voted. The deal is expected to close in H2 2026, pending China's State Administration for Market Regulation (SAMR), which requested additional information in late May 2026 after a formal antitrust complaint slowed the expedited review.

CEO Mike Hsu framed this as "the next step in our Powering Care transformation" — creating a $32 billion revenue health-and-wellness leader with $2.1 billion in expected annual synergies and accretion to adjusted EPS by year two.

The market heard something different: dilution, debt, and lawsuits.

Named cause 2: the IFP exit shrank the revenue base. In parallel, Kimberly-Clark sold a 51% stake in its International Family Care and Professional (IFP) business — tissue, paper towels, and wipers across Europe, Africa, South America, Asia, and the Middle East — to Brazilian pulp giant Suzano. The EU unconditionally approved the deal in May 2026. The IFP exit is how full-year 2025 revenue dropped from $20.1 billion (FY2024) to $16.4 billion (FY2025) — not because the core business shrank, but because Kimberly-Clark carved off the lower-margin international tissue operations to fund the higher-margin Kenvue acquisition.

The optically ugly revenue drop masked a fundamentally sound core: Q1 2026 delivered $4.16 billion in net sales (+2.7% YoY), organic sales growth of +2.5%, volume-plus-mix growth of +3.0%, and adjusted EPS of $1.97 that beat the $1.93 consensus. This was the ninth or tenth consecutive quarter of volume-driven organic growth. Gross productivity hit 6% — matching the rate Kimberly-Clark has sustained for two straight years.

The unnamed cause: the lawsuits that came with Kenvue. This is where the cradle meets the courtroom.

Kenvue inherits two massive litigation tails from Johnson & Johnson. The first is talc: more than 73,000 plaintiffs allege that J&J baby powder and other talc-based products caused cancer. J&J has failed to resolve these claims in bankruptcy three times, and the cases are moving forward in both federal and state courts. The second is Tylenol: hundreds of lawsuits consolidated in multidistrict litigation allege that acetaminophen during pregnancy caused children's autism or ADHD. A U.S. appeals court is hearing arguments over whether to revive these claims. The Texas Attorney General has filed a separate action under the state's deceptive trade practices law, and a judge denied Kenvue's motion to dismiss.

Kenvue CEO Kirk Perry has said the company stands "firmly behind the science and the safety of our products." But the litigation tail is measured in tens of thousands of plaintiffs, not in confidence statements.

And Kimberly-Clark has its own: a November 2025 class action alleges that Huggies Little Movers diapers were quietly reformulated, causing severe skin reactions including chemical burns in infants. Parents claim the company marketed the diapers as "hypoallergenic" while changing the composition without disclosure. This follows a 2022 class action over Ahcovel, a known skin irritant used in Huggies to increase absorbency, which was dismissed after confidential settlement.

That is how Kimberly-Clark got to $99.

The company is not dying. It is transforming. Revenue declined on paper because of a deliberate divestiture, not because consumers stopped buying Huggies and Kleenex. The core business is accelerating.

*FY2025 revenue decline reflects IFP business exit to Suzano, not organic deterioration.

The story this table tells is "a 150-year-old staples company deliberately shrinking its lower-margin international tissue business to fund an acquisition that doubles its revenue and adds higher-margin health-and-wellness brands." The standalone core is healthy: volume-driven organic growth accelerating, productivity discipline at industry-leading rates, and a dividend the company has increased for 54 consecutive years.

The question is not whether the core Kimberly-Clark is broken. It isn't. The question is whether the $48.7 billion check it wrote to buy Kenvue comes with a litigation bill that swallows the synergies.

Every claim about consumer or employee sentiment in this report is sourced and counted. Here is what was surveyed.

Important note on sample sizes: Kimberly-Clark is a consumer staples company, not a consumer brand with a loyalty community. People do not leave Trustpilot reviews for toilet paper and diapers the way they do for athleisure or restaurants. The consumer review footprint is thin by design — these are products bought on autopilot, not on passion. The complaint-channel data is a grievance signal, not a representative sample of the 1-in-4 households that buy KMB products. We flag this throughout the analysis.

The question matters because if the 1-star complaint concentration is Huggies-specific, it signals a product crisis. If it matches the category, it signals the nature of how consumers review commodity products — which is only when something goes wrong.

Test: Two-proportion Z-test on Trustpilot 1-star share.

Huggies US Trustpilot: 51 of 68 reviews are 1-star (75.0%). Pampers Germany Trustpilot: 17 of 25 reviews are 1-star (68.0%).

Under a null hypothesis that both brands draw from the same grievance-skewed population of reviewers:

Result: We cannot reject the null. The 1-star concentration on Huggies (75%) is not statistically distinguishable from Pampers (68%) at any conventional significance level. The p-value of 0.50 means the observed difference is well within random noise given the sample sizes.

Interpretation: The complaint-channel data does NOT show a Huggies-specific crisis distinct from the broader diaper category. Both brands show extreme 1-star skew because Trustpilot for consumer staples is functionally a complaint board — the only parents who find their way to Trustpilot for diapers are parents whose baby got a rash.

This does NOT mean the Huggies class action is meritless. It means the Trustpilot data cannot distinguish a formulation-change signal from normal category noise. The class action is a legal question, not a rating-distribution question.

Test: Mann-Kendall trend test on monthly KMB closing prices, June 2025 to June 2026.

Result: The null hypothesis of no trend is rejected at p < 0.0001. The declining trend is statistically significant and monotonic — every month from July 2025 through April 2026 saw a lower close than the month before.

The slight uptick in May-June 2026 (from $96.1 to $99.1) breaks the monotonic decline but does not invalidate the overall trend. The Mann-Kendall S-statistic is robust to small end-of-series reversals.

95% CI on the trend magnitude: The stock declined from $144.23 (52-week high) to $92.42 (52-week low), a maximum drawdown of 35.9%. At $99.14, it remains 31.2% below the high.

The P&L shows a company executing well on its standalone base. What it does not show is the integration risk of the largest acquisition in Kimberly-Clark's 153-year history.

What the 6% productivity doesn't capture: Kimberly-Clark's gross productivity of 6% — sustained for two consecutive years and on track for a third — is industry-leading for consumer staples. But that productivity is being generated on a $16.4 billion revenue base. Post-Kenvue, the combined entity will be a $32 billion company with approximately 60,000+ employees across entirely different product categories (baby care and tissue vs. OTC pharma, oral care, and skincare). Sustaining 6% productivity through that integration is an assumption, not a fact.

What the $2.1 billion synergy target doesn't capture: Synergies assume execution. They also assume that the Tylenol and talc litigation does not absorb management attention and balance-sheet capacity that would otherwise fund integration. The breakup fee is ~$1 billion if either side walks away. SAMR's request for additional information in late May 2026 is a yellow light, not a red light — but it is not a green light either.

What the dividend doesn't capture: The 5.26% yield and 54-year streak are genuinely impressive for a Dividend Aristocrat. But the Kenvue deal will fund $6.7 billion in cash payments plus new debt issuance. Post-close, the combined company's payout ratio and leverage will reset. The dividend is safe today. Whether it's safe at the combined entity's leverage ratio in 2027 is the question the market is asking.

Recovering:

NOT recovering:

Unknown (and unknowable until H2 2026):

On the consumer data: The consumer review sample (396 reviews across all platforms) is thin relative to the brands' reach. Kimberly-Clark products are in roughly 25% of households globally. The Trustpilot and PissedConsumer footprint for consumer staples is structurally complaint-skewed and cannot be treated as representative of the broader customer base. The two-proportion Z-test on Huggies vs. Pampers 1-star share (Z = 0.675, p = 0.50) fails to reject the null — the Huggies complaint pattern is not statistically distinguishable from the category. We state this explicitly because the sample sizes are below the floors we apply to TR reports on consumer-facing brands with larger review footprints.

On the Kenvue litigation: Litigation outcomes are binary and unpredictable. The talc and Tylenol cases could settle for less than feared, vindicating the acquisition. Or they could escalate, consuming balance-sheet capacity and management attention for years. We do not model litigation outcomes. We note the exposure.

On the Huggies class action: The November 2025 class action is active but early-stage. The 2022 class action over Ahcovel was dismissed after confidential settlement. Product liability litigation for consumer goods companies is common and does not, on its own, signal a broken brand. What would signal a broken brand is sustained market share loss in the Huggies franchise — and the data does not show that. Huggies holds approximately 20% global market share vs. Pampers at ~25%.

Kimberly-Clark at $99 is one of two things. Either it is a Dividend Aristocrat with a healthy core business temporarily depressed by deal-related dilution fear and a litigation overhang on the target — in which case $99 is a gift for income investors willing to hold through integration. Or it is a value trap: a staples company that overpaid for a lawsuit magnet, and the 5.26% yield is compensation for the tail risk, not an invitation to buy.

Expected value at probability-weighted midpoints: ~$113. Current price: $99.14. The gap is 14%, but the distribution is wide — the bull case has real upside and the bear case has real downside.

Now ($99.14): The dividend yields 5.26% — 54 consecutive years of increases. The standalone business is growing organically at 2.5%+ with best-in-class productivity. The stock is 31% off its high and trades at a depressed multiple because of deal uncertainty, not operational failure. For income investors, the yield alone pays you to wait.

At Q2 earnings (July 28, 2026): Management will update on Kenvue close timing, SAMR review status, tariff mitigation progress, and standalone organic growth trajectory. If organic growth re-accelerates above +3% and SAMR signals clearance, the stock re-rates to $110+ before the deal even closes. If SAMR stalls or the Huggies class action attracts regulatory attention, the stock tests $92 again.

Decider date: H2 2026 deal close. The Kenvue transaction is the single largest event in Kimberly-Clark's 153-year history. If it closes cleanly with SAMR approval and no adverse litigation developments, the combined entity is a $32 billion health-and-wellness leader with $2.1 billion in synergies and a portfolio spanning baby care, tissue, oral care, skincare, and OTC pharma. If it doesn't close, the breakup fee is ~$1 billion and standalone KMB reprices to its fundamentals — which are quietly solid.

When Kimberly-Clark reports Q2 2026 earnings on July 28, Turnaround Radar will publish the follow-up. We will track: (1) whether SAMR has cleared the Kenvue deal, (2) whether organic growth sustained above +2.5%, (3) any update on the Huggies class action, and (4) the first post-close integration guidance if the deal closes before the call.

The cradle is solid. The courtroom is filling up. July 28 tells us which room matters more.